Dr. Adam Brufsky, MD
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Breast Cancer
Expert in Breast cancer
31 reported clinical trials
70 drugs studied
Area of expertise
1Breast Cancer
Global LeaderStage IV
ER positive
Stage III
2Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
Affiliated Hospitals
Clinical Trials Adam Brufsky, MD is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
More about Adam Brufsky, MD
Clinical Trial Related1 year of experience running clinical trials · Led 31 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Adam Brufsky, MD has experience with
- Paclitaxel
- Trastuzumab
- Abemaciclib
- Pertuzumab
- Olaparib
- Enobosarm
Breakdown of trials Adam Brufsky, MD has run
Breast Cancer
Breast cancer
Skin Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam Brufsky, MD specialize in?
Adam Brufsky, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER positive.
Is Adam Brufsky, MD currently recruiting for clinical trials?
Yes, Adam Brufsky, MD is currently recruiting for 7 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Adam Brufsky, MD has studied deeply?
Yes, Adam Brufsky, MD has studied treatments such as Paclitaxel, Trastuzumab, Abemaciclib.
What is the best way to schedule an appointment with Adam Brufsky, MD?
Apply for one of the trials that Adam Brufsky, MD is conducting.
What is the office address of Adam Brufsky, MD?
The office of Adam Brufsky, MD is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.